Meridian Bioscience Inc

Meridian Bioscience — FY2019 Earnings Presentation

24 slides from Meridian Bioscience's earnings presentation, Nov 7, 2019

  1. Slide 1: FY2019 Q4 and Year End Results

    Exhibit 99.2 MerPIdIAN sioscience- wT FY2019 Q4 and Year End Results November 7, 2019

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within

  3. Slide 3: Forward Looking Statements (continued)

    Forward Looking Statements (continued) All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of Meridian that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncert

  4. Slide 4: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of acquisition-related costs, restructuring costs, selected legal costs, and certain o

  5. Slide 5: Q4 2019 Business Highlights

    Q4 2019 Business Highlights Diagnostics Life Science • Meaningful stabilization of business • Record revenues and profitability • Consistent revenues Q3 to Q4 • Revenues $17.4 million • Adjusted operating income $6 million • Revogene™ molecular system launch and 34% margin • Solid Commercial Team ex

  6. Slide 6: 2019 Fourth Quarter Earnings Summary

    2019 Fourth Quarter Earnings Summary ($000s except per share amounts) Adjusted (Non-GAAP) 2019 2018 Change Highlights Revenue $50,846 $53,100 -4.2% • Diagnostics revenues down 9% but stable with Q3. Gross Margin 57.3% 60.6% -3.3 pts • Life Science revenues up 7%. Operating expenses¹ $21,593 $20,470

  7. Slide 7: 2019 Fiscal Fourth Quarter Operating Segment Highlights

    2019 Fiscal Fourth Quarter Operating Segment Highlights ($000’s) Diagnostics (Adjusted Non-GAAP) Life Science (Adjusted Non-GAAP) 2019 2018 Change 2019 2018 Change Revenue $33,399 $36,814 -9.3% Revenue $17,447 $16,286 +7.1% Operating income $3,171 $8,358 -62.1% Operating income $5,954 $4,719 +26.2%

  8. Slide 8: 2019 Fiscal Year Earnings Summary

    2019 Fiscal Year Earnings Summary ($000s except per share amounts) Adjusted (Non-GAAP) 2019 2018 Change Highlights Revenue $201,014 $213,571 -5.9% • Diagnostics revenues down 9%. Gross Margin 58.9% 61.2% -2.3 pts Operating expenses¹ $79,396 $86,062 -7.7% • Life Science revenues up 2%. Ratio 39.5% 40

  9. Slide 9: 2019 Fiscal Year Operating Segment Highlights

    2019 Fiscal Year Operating Segment Highlights ($000’s) Diagnostics (Adjusted Non-GAAP) Life Science (Adjusted Non-GAAP) 2019 2018 Change 2019 2018 Change Revenue $136,682 $150,454 -9.2% Revenue $64,332 $63,117 +1.9% Operating income $25,845 $36,601 -29.4% Operating income $20,760 $15,039 +38.0% % Ma

  10. Slide 10: 2020 Fiscal Year Guidance

    2020 Fiscal Year Guidance Meridian Bioscience Consolidated net revenues: Down 3% to Flat Adjusted operating margin: 9% to 10% Tax rate: 23.5% to 24.5% Adjusted earnings per share: $0.28-$0.34 Research and development spend: $27 to $28 Million Life Science Diagnostics �� Net revenues: Down 3% to 5% N

  11. Slide 11: Investing in our Transformation

    Investing in our Transformation ($Millions) $38.9 -$11.0 $3.3 $19.8 -$5.0 -$2.4 -$4.0 2019 Adjusted Dx New Dx Margin and People and Revogene Cost 2020 Adjusted Operating Income Product Revenue Erosion Culture Purchase Savings and Operating Income Development Investments Accounting Other Spend Amorti

  12. Slide 12: Business Turnaround Update

    Business Turnaround Update —wT

  13. Slide 13: Key Elements of Meridian's Strategy

    Key Elements of Meridian’s Strategy • Growth orientation Re-shape the • Focus and concentrate resources on core financial profile • Address areas of vulnerability • Organic and inorganic Focused, new • Jump start R&D, accelerate pipeline investment to • Proactive and programmatic M&A support growth

  14. Slide 14: Transformation Process

    Transformation Process Sustainable revenue and Product portfolio Commercial profit growth Reshape culture Continuous investment execution • New Leadership • Revogene™ acquisition• Commercial improvement • Performance culture • Improved new product Excellence • Reward & Recognition Cost structure dev

  15. Slide 15: Reshaping Our Diagnostics Business

    Reshaping Our Diagnostics Business —w

  16. Slide 16: Conversion of Molecular Customers

    Conversion of Molecular Customers GenePOC acquisition Assay Revenue C. difficile ü ü 2020 Group A Strep ü ü Time Current trend of Stabilize and Sustainably grow Group B Strep Meridian protect base with the base with ü ü molecular Alethia menu expansion All other MDx assays revenues conversions and i

  17. Slide 17: Revogene Install Base Highlights

    Revogene™ Install Base Highlights 80 70 • Initial customer demand greater than anticipated 60 • In the process of ramping 50 up instrument and pie 40 manufacturing 70 30 • Our goal is >250 units in our install base by June 30, 20 2020 10 10 0 Acquired Install Base Install Base as of Future 9/30/19Re

  18. Slide 18: Revogene Manufacturing – Scale Up

    Revogene™ Manufacturing – Scale Up Acquisition Kits manufactured Current FutureRevogene™ Manufacturing – Scale Up Acquisition Kits manufactured Current Future

  19. Slide 19: Diagnostics: New Product Development

    Diagnostics: New Product Development R&D Spend as a % of Diagnostics Segment Revenues 20% 19% Highlights 18% • Reshaped new product 16% development process in FY 18 • Heavy investment mode 14% beginning in FY 19 and continuing 12% 11% into FY 20 and 21, including clinical trials 10% 9% • R&D program

  20. Slide 20: Diagnostics: Clinical Trial Investment

    Diagnostics: Clinical Trial Investment Platform 2020 2021 • Dramatic increase in the GI Depth GI Panel Carba (swab) Dual Technology RI Panel RI Panel clinical trial spend over IA + MDx next two fiscal years • Allows selling across IDNs (small to large) • Allows best-in-class technology for each assa

  21. Slide 21: Life Science

    Life Science —

  22. Slide 22: Life Science: Building a Stronger Business

    Life Science: Building a Stronger Business ü Complete Reshape business to drive improved profitability → In progress GOALS Continue high growth global business Life Science: Building a Stronger Business ü Complete Reshape business to drive improved profitability → In progress GOALS Continue high gro

  23. Slide 23: Meridian's Strategy Summary

    Meridian’s Strategy Summary • Target IDN needs• Bulk raw materials: IA + MDx • IA, Blood-chem and MDx • High volume customers platforms• Leverage consolidated structure • New growth orientation • Deep GI expertise and menu• Global market potential • Focus resources on core target • Pediatric POC: le

  24. Slide 24: Questions & Answers

    Questions & Answers eww”

Meridian Bioscience — FY2019 Earnings Presentation on 6ix